Leveraging our unparalleled expertise in diseases of the immune system and CXCR4 biology, we aim to bring innovative treatments to people with chronic neutropenic disorders.
Our lead product candidate, mavorixafor, is designed to enable mobilization of immune cells from the bone marrow into the bloodstream to improve immune system function.
- X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
- X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
- X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update